Meta-analysis of the relationship between montelukast use and neuropsychiatric events in patients with allergic airway disease

Yakui Mou; Qing Song; Chunying Zhao; Han Fang; Chao Ren; Xicheng Song

doi:10.1016/j.heliyon.2023.e21842

Meta-analysis of the relationship between montelukast use and neuropsychiatric events in patients with allergic airway disease

Heliyon. 2023 Nov 8;9(11):e21842. doi: 10.1016/j.heliyon.2023.e21842. eCollection 2023 Nov.

Authors

Yakui Mou^{1

2

3}, Qing Song⁴, Chunying Zhao⁵, Han Fang¹, Chao Ren^{2

3

6}, Xicheng Song^{1

2

3}

Affiliations

¹ Department of Otorhinolaryngology Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong Province, 264000, China.
² Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai, Shandong Province, 264000, China.
³ Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai, Shandong Province, 264000, China.
⁴ Department of Otolaryngology, Yantai YEDA Hospital, Yantai, Shandong Province, 264000, China.
⁵ Epilepsy Sleep Center, Linyi People Hospital, Linyi, Shandong Province, 276000, China.
⁶ Department of Neurology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong Province, 264000, China.

Abstract

Use of montelukast, as a cause of neuropsychiatric events, in patients with asthma or allergic rhinitis is controversial, and comprehensive statistical analyses verifying this relationship remain lacking. To better understand the relationship between montelukast and neuropsychiatric events, it is vital to guide patients in the effective use of the drug, especially in children whose mothers are concerned about its side effects. In this study, randomized controlled trials (RCTs) investigating montelukast and neuropsychiatric events were retrieved from a literature search of the Medline (1966 to February 2023), Embase (1974 to February 2023), Web of Science, and other related databases. After screening, 18 RCTs were ultimately included in a meta-analysis to merge statistics, which demonstrated no significant increase in neuropsychiatric events compared with placebo. A similar pattern of adverse neuropsychiatric events was observed in patients grouped according to age, with headache being the most common adverse neuropsychiatric event. Overall, montelukast did not significantly increase neuropsychiatric events in patients with allergic rhinitis and/or asthma compared with placebo. Large-sample RCTs are needed to verify the association between neuropsychiatric events and montelukast use in children, and attention is also devoted to FDA warnings.

Keywords: Allergic airway disease; Allergic rhinitis; Asthma; Children; Montelukast; Neuropsychiatric event.